Karyopharm Therapeutics Company

Karyopharm Therapeutics is working on XPOVIO® (selinexor), a first-in-class, oral selective inhibitor of nuclear export (SINE), designed to block the cellular protein XPO1. Selinexor was granted FDA accelerated approval in July 2019 in combination with dexamethasone as a treatment for some adults with relapsed refractory multiple myeloma.

Karyopharm said April 7 it will initiate a global randomized clinical trial evaluating low dose oral selinexor in hospitalized patients with severe COVID-19. The company noted that SINE compounds have been shown to disrupt the replication of multiple viruses in vitro and in vivo, and to mediate anti-inflammatory and anti-viral effects, including respiratory infections, in several animal models. Karyopharm cited a preprint study published March 20 in bioRxiv identifying SINE compounds as having the potential to interfere with key host protein interactions with SARS-CoV-2.

Investors

Funding Status: N/A
Headquarters: United States
Founded Date: N/A
Investor Type: N/A
Investment Stage: N/A
Technology: COVID
Employee Number: N/A
Number Of Exists: N/A
Industry: Treatments
N/A
Register and Claim Ownership